Objective:To observe the clinical efficacy and influence of ginsenoside combined with temozolomide on the levels of HGF, TNF-α and IL-17 in cerebrospinal fluid of postoperative patients with brain glioma. Methods90 postoperative patients with brain glioma were divided into the treatment group and the control group,45 cases in each group. The control group was treated with temozolomide, the treatment group was treated with ginsenoside Rg3 based on the treatment for control group,with a course of 6 treatment cycles. The overall survival (OS), progression-free survival (PFS), and the levels of HGF, TNF-α and IL-17 in cerebrospinal fluid before and after treatment were compared.  Results:After treatment,the OS and PFS in the treatment group were significantly longer than those in the control group (P<0.05); after treatment,the levels of HGF, TNF-α and IL-17 in cerebrospinal fluid of patients in both groups were significantly decreased compared with the treatment before(P<0.05, P<0.01), and the levels of HGF, TNF-α and IL-17 in the treatment group were significantly lower than those in the control group(P<0.05).  Conclusion:Ginsenoside Rg3 combined with the temozolomide can inhibit the growth and proliferation of brain glioma and prolong the survival time of patients.